Liquidia 与 UTHR 达成 3.807 亿美元诉讼和解后，股价飙升 40%

Open in App

Popular Searches

Please try another search

Top Brokers

Image 1: Plus500

Plus500

4.9

★★★★★

Open Account

Read Review

eToro

4.8

★★★★★

Open Account

Read Review

Tools

Calendars * Economic Calendar * Holiday Calendar * Earnings Calendar * Dividend Calendar * Splits Calendar * IPO Calendar * Futures Expiry Calendar

Investment Tools

*   [Stock Screener](https://www.investing.com/stock-screener)
*   [Fed Rate Monitor Tool](https://www.investing.com/central-banks/fed-rate-monitor)
*   [Currency Converter](https://www.investing.com/currency-converter/)
*   [Fibonacci Calculator](https://www.investing.com/tools/fibonacci-calculator)

Liquidia stock surges 40% on $380.7M litigation settlement with UTHR

AuthorLuke Juricic

Stock Markets

Published Oct 13, 2026, 05:56 PM

Liquidia stock surges 40% on $380.7M litigation settlement with UTHR

View all comments (0)0

Liquidia stock surges 40% on $380.7M litigation settlement with UTHR

View all comments (0)0

Image 3: © Reuters

In this article:

LQDA-3.11%

Investing.com -- Liquidia Corporation (NASDAQ:LQDA) shares jumped around 40% in after-hours trading Tuesday following the announcement of a global settlement agreement with United Therapeutics Corporation (NASDAQ:UTHR) that resolves all pending litigation between the companies for $380.7 million.

The settlement fully resolves six ongoing lawsuits and ensures uninterrupted access to YUTREPIA (treprostinil) inhalation powder for patients with pulmonary arterial hypertension. As part of the agreement, Liquidia will pay a net $175 million within 30 business days, followed by two equal installments of $72.7 million due on or before January 31, 2027, and April 30, 2027.

Analyze LQDA with InvestingPro - Get 50% off now

The settlement follows a September 30, 2026 ruling by the U.S. District Court for the District of Delaware that claims of U.S. Patent No. 11,826,327 are valid and infringed by Liquidia. The patent covers treatment of pulmonary hypertension associated with interstitial lung disease with inhaled treprostinil. Liquidia has agreed not to appeal the ruling and has submitted a supplement to remove the PH-ILD indication from YUTREPIA's label.

In connection with the settlement, Liquidia will pay an aggregate of $60.3 million this month to parties with interests in antitrust litigation related to Treprostinil Injection. The company has also terminated the promotional agreement for Treprostinil Injection and will no longer commercially support the product.

Liquidia reported preliminary, unaudited third quarter 2026 YUTREPIA net product sales of $222.7 million, contributing to cash and cash equivalents of $396.1 million as of September 30, 2026. The company expects to fund the settlement payments from ongoing YUTREPIA sales and cash on hand without requiring additional financing.

Liquidia

Analyze LQDA

Included in our AI-picked strategies

Review strategies

26.81

▼-0.860(-3.11%)

Closed·15:59:59·USD

37.969

▲+11.159(+41.62%)

After Hours·22:02:36

Max

Start trading LQDA now

Trade

Analyze LQDA

Trade

The settlement includes mutual releases and is not an admission of liability by either party. Liquidia will provide a broader update on its financial position and pipeline priorities during its third-quarter 2026 earnings call in November.

Is LQDA in any of our AI strategies?

ProPicks AI re-scores LQDA every month against thousands of alternatives on 100+ financial metrics, then builds the strategies that came out ahead.

Energy Elite is beating its benchmark by 37% year to date. Mid Cap Movers by 21%. Tech Titans, our flagship, has beaten the S&P 500 by 112% since launch three years ago.

See whether LQDA made the cut — and which stocks did.

See the AI Picks

Liquidia stock surges 40% on $380.7M litigation settlement with UTHR

View all comments (0)0

Latest comments

Post

Comment Guidelines

Loading next article…

Trade With A Regulated Broker

Indices Commodities Bonds Stocks

Max

US 30

51,676.40

-173.9

-0.34%

US 500

7,807.40

+0.2

0.00%

Dow Jones

51,670.10

-180.45

-0.35%

S&P 500

7,805.64

-1.60

-0.02%

Nasdaq

27,204.38

-41.52

-0.15%

S&P 500 VIX

15.27

+0.06

+0.39%

Dollar Index

101.989

+0.009

+0.01%

Crude Oil WTI Futures

94.79

+1.05

+1.12%

Brent Oil Futures

106.21

-0.14

-0.13%

Natural Gas Futures

3.32

+0.150

+4.80%

Gold Futures

4,184.80

+7.50

+0.18%

Silver Futures

59.418

-0.113

-0.19%

Copper Futures

6.7308

+0.0007

+0.01%

US Soybeans Futures

1,282.75

0.00

0.00%

U.S. 10Y

5.213

-0.004

-0.08%

U.S. 30Y

5.565

-0.034

-0.61%

U.S. 5Y

5.009

-0.013

-0.26%

U.S. 3M

4.164

0.000

0.00%

US 10Y T-Note Futures

104.75

+0.19

+0.18%

Euro Bund Futures

121.06

+0.10

+0.08%

10-2 Yield Spread

31.32

+4.15

+15.27%

AAPL

341.27

+0.30

+0.09%

NVDA

228.51

+2.19

+0.97%

GOOGL

353.78

+1.06

+0.30%

TSLA

375.23

-2.80

-0.74%

AMZN

258.58

-0.95

-0.37%

NFLX

70.46

-0.15

-0.21%

Name	Last	Chg. %	Vol.
CDW	151.97	+5.71%	2.42M
VLO	456.37	+4.67%	2.16M
CHTR	106.95	+4.36%	2.88M
ORCL	143.20	+4.23%	22.40M
PSX	292.73	+4.00%	1.71M
MPC	476.98	+3.96%	1.30M
FSLR	186.60	+3.83%	2.27M

Name	Last	Chg. %	Vol.
AMAT	464.24	-6.69%	10.46M
JNJ	248.61	-5.73%	13.51M
C	124.53	-5.60%	18.15M
DPZ	296.10	-4.76%	2.01M
KKR	87.16	-4.75%	7.26M
VRTX	485.22	-4.30%	1.06M
SPCX	156.54	-4.21%	66.42M

Trending Stocks

Name	Last	Chg. %	Vol.
MU	952.95	-3.65%	26.50M
SNDK	1,482.33	-0.34%	8.06M
NVDA	228.51	+0.97%	65.47M
JPM	331.43	-0.86%	11.44M
SPCX	156.54	-4.21%	66.42M

ProPicks AI

AI-powered stock picks with a proven track record to beat the S&P 500.

Tech Titans

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Top Value Stocks

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Best of Buffett

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Energy Elite

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Financial Fortresses

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Quality Compounders

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Small-Cap Sprinters

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Healthcare Heroes

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Beat the S&P 500

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Dominate the Dow

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Mid-Cap Movers

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Mexican Stock Exchange Leaders

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Best Brazilian Stocks

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Italian Market Elite

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Alpha Germany Select

Stocks in this Strategy

aaaa aaaaa aaaa a

Unlock Strategy

Comments

Post

Comment Guidelines

Calendars

Economic Calendar Earnings Calendar Holiday Calendar

US Economy

Fed Rate Monitor Tool US Treasury Yield Curve

More Tools

Stock Screener Currency Converter

Markets Ask WarrenAI Stocks Picked by AI Watchlist Alerts Top Brokers Breaking News Tools

Install Our App Scan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.Fusion Mediaand any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.